HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions.

AbstractBACKGROUND:
Antibiotics, such as inhaled tobramycin, are used to eradicate new-onset Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF) but frequently fail due to reasons poorly understood. We hypothesized that PA isolates' resistance to neutrophil antibacterial functions was associated with failed eradication in patients harboring those strains.
METHODS:
We analyzed all PA isolates from a cohort of 39 CF children with new-onset PA infections undergoing tobramycin eradication therapy, where 30 patients had eradicated and 9 patients had persistent infection. We characterized several bacterial phenotypes and measured the isolates' susceptibility to neutrophil antibacterial functions using in vitro assays of phagocytosis and intracellular bacterial killing.
RESULTS:
PA isolates from persistent infections were more resistant to neutrophil functions, with lower phagocytosis and intracellular bacterial killing compared to those from eradicated infections. In multivariable analyses, in vitro neutrophil responses were positively associated with twitching motility, and negatively with mucoidy. In vitro neutrophil phagocytosis was a predictor of persistent infection following tobramycin even after adjustment for clinical risk factors.
CONCLUSIONS:
PA isolates from new-onset CF infection show strain-specific susceptibility to neutrophil antibacterial functions, and infection with PA isolates resistant to neutrophil phagocytosis is an independent risk factor for failed tobramycin eradication.
AuthorsKelly Kwong, Andrea Benedetti, Yvonne Yau, Valerie Waters, Dao Nguyen
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 225 Issue 11 Pg. 1886-1895 (06 01 2022) ISSN: 1537-6613 [Electronic] United States
PMID33606875 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Chemical References
  • Anti-Bacterial Agents
  • Tobramycin
Topics
  • Anti-Bacterial Agents (pharmacology, therapeutic use)
  • Cystic Fibrosis (complications, microbiology)
  • Humans
  • Neutrophils
  • Pseudomonas Infections (microbiology)
  • Pseudomonas aeruginosa (genetics)
  • Tobramycin (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: